La Trobe

Case report: Partial regression of metastatic squamous cell carcinoma with altered azathioprine dosage after long-term use in renal transplant patient

Download (1.71 MB)
journal contribution
posted on 2024-12-12, 02:07 authored by Tegan Ormston, Jessica da Gama DuarteJessica da Gama Duarte, Luke T Quigley, Louise Jackett, John Whitlam, Andreas BehrenAndreas Behren, David E Gyorki

Introduction: We report the partial regression of metastatic squamous cell carcinoma (SCC) after reduction of long-term azathioprine therapy while awaiting surgery. The patient was a 69-year-old man with a history of kidney transplantation. Moderately differentiated SCC arising in the anterior neck was initially diagnosed, followed later by poorly differentiated SCC metastases to cervical lymph nodes. Lymph node clearance was performed 28 days after a reduction in azathioprine dosage. The palpable lymph node lesion had noticeably decreased in size at the time of surgery, and subsequent histology only detected 7mm and 0.2mm deposits of poorly differentiated SCC in 2 of 5 level I nodes, and a further 10 reactive nodes from levels II and III. One positive level I and another benign level II/III node, demonstrated necrosis, histiocytic infiltration and fibrosis, interpreted as features of regression. Hence, we investigated the role of immune cells in the partial regression of metastatic SCC after reduction of long-term azathioprine therapy while awaiting surgery.

Methods: Multispectral immunohistochemistry using custom markers was performed on regions of interest of excised cervical lymph nodes, encompassing the entire SCC deposit and the surrounding adjacent stroma to quantify to number and types of immune cells present.

Results: Multispectral immunohistochemistry revealed the heavy infiltration of activated T cells in the tumour, as well as PD-L1+ antigen-presenting cells in the surrounding adjacent stroma, suggesting an immunologically mediated partial regression.

Discussion: We hypothesize that this reaction was triggered by azathioprine dose reduction. Dose modification of long-term immunosuppressive medications in patients with a transplantation history who later develop SCCs warrants further investigation.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The Olivia Newton-John Cancer Research Institute acknowledges the support of the Victorian Government Operational Infrastructure Support Program and the Ian Potter Foundation for providing funds to purchase the Vectra System. JD was supported by Cure Cancer Australia through the Cancer Australia Priority-driven Cancer Research Scheme (#1187815). AB was supported by a fellowship from the Department of Health and Human Services acting through the Victorian Cancer Agency (VCA) and by a grant from Tour de Cure.

History

Publication Date

2024-10-31

Journal

Frontiers in Immunology

Volume

15

Article Number

1474663

Pagination

6p.

Publisher

Frontiers

ISSN

1664-3224

Rights Statement

© 2024 Ormston, Da Gama Duarte, Quigley, Jackett, Whitlam, Behren and Gyorki. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.